LIPAC Oncology Names Daniel K. Spiegelman as Independent Board Advisor

MENLO PARK, Calif., May 13, 2021 /PRNewswire/ — LIPAC Oncology LLC., a pharmaceutical company utilizing its liposome-bound nano-technology platform to provide precision targeted cancer drugs for the treatment of multiple tumor types, today announced the appointment of Daniel K….

About the Author

has written 41816 stories on this site.

Copyright © 2010 Business and Corporate News.